News this week of results from Intellia Therapeutic’s first-in-human clinical trial captured the world’s imagination. The phase 1 trial demonstrated for the first time that direct CRISPR/Cas9 genome editing works in humans. Intellia are far from the only company working on this technology.
Direct editing of the human genome in vivo
Direct editing of the human genome in vivo
Direct editing of the human genome in vivo
News this week of results from Intellia Therapeutic’s first-in-human clinical trial captured the world’s imagination. The phase 1 trial demonstrated for the first time that direct CRISPR/Cas9 genome editing works in humans. Intellia are far from the only company working on this technology.